

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): December 14, 2021**

**SeaSpine Holdings Corporation**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36905**  
(Commission  
File Number)

**47-3251758**  
(I.R.S. Employer  
Identification No.)

5770 Armada Drive, Carlsbad, CA 92008  
(Address of principal executive offices) (zip code)

**Registrant's telephone number, including area code: (760) 727-8399**

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.01 per share	SPNE	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02**                      **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 14, 2021, our board of directors unanimously elected Angela Steinway, effective that day, as a Class III director and appointed her to the audit committee of our board of directors.

Ms. Steinway was elected upon the recommendation of our nominating and corporate governance committee. Our board of directors determined that Ms. Steinway qualifies as an independent director under applicable SEC and Nasdaq rules. There was no arrangement or understanding between Ms. Steinway and any other person under which she was elected to our board of directors. As a Class III director, Ms. Steinway will next be up for election at our 2024 annual meeting of stockholders.

Ms. Steinway will be compensated in accordance with our standard compensation policies and practices for non-employee directors, the components of which were disclosed in our proxy statement for our 2021 annual meeting of stockholders dated April 21, 2021, and which consists of annual retainers and equity-based compensation. In accordance with our standard compensation policies and practices for non-employee directors, upon election to our board of directors, Ms. Steinway was granted a restricted stock award covering 7,782 shares of our common stock, which is equal to \$100,000 divided by the per share fair market value of our common stock on the date of her election, and which will vest in full on the one-year anniversary of the grant date, subject to continued service through the vesting date and subject to earlier vesting upon death or disability. We also entered into our standard director and officer indemnification agreement with Ms. Steinway.

We issued a press release announcing the appointment of Ms. Steinway to our board of directors, a copy of which is furnished as Exhibit 99.1.

**Item 9.01**                      **Financial Statements and Exhibits.**

(d) *Exhibits*

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press release issued December 14, 2021</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SeaSpine Holdings Corporation

By: /s/ Patrick Keran

Name: Patrick Keran

Title: Senior Vice President, General Counsel

Date: December 14, 2021



### SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

**CARLSBAD, CA / December 14, 2021** – SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company’s Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent.

Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she is the Vice President, Strategy, Business Development, and Private Label at Integra Lifesciences Holdings Corporation where she oversees strategy and business development for tissue technologies and regenerative medicine and has responsibility for an approximately \$120 million business serving non-core commercial markets. Ms. Steinway joined Integra in 2009 and, prior to her current role, held roles of increasing responsibility within the company’s finance and sales organizations. Earlier in her career, Ms. Steinway worked at Oppenheimer & Co (formerly CIBC World Markets) as a Securities Analyst, Medical Devices & Diagnostics Equity Research where her research focused on the medical technology industry.

“We are pleased to welcome Angela to SeaSpine’s Board of Directors,” said Keith Valentine, SeaSpine President and Chief Executive Officer. “Angela’s passion for life science technologies, combined with her experience in identifying and pursuing strategic opportunities, will provide us with unique insight as we move through our next stages of growth. We look forward to working with Angela in meeting our corporate strategic goals.”

Kirt Stephenson, the Chair of SeaSpine’s Board of Directors, said: “Angela’s addition complements our Board’s existing skills and experiences. We are excited about the new perspective she will bring.”

Ms. Steinway earned her B.A. in Economics from the University of Pennsylvania and holds an Executive Education Certificate from the Wharton School of the University of Pennsylvania. She currently sits on the board of ProduceGood, an organization dedicated to finding sustainable solutions to alleviate hunger, reclaim and repurpose waste and promote community health.

#### About SeaSpine

SeaSpine ([www.seaspine.com](http://www.seaspine.com)) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software, and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

###

Investor Relations Contact  
Leigh Salvo  
(415) 937-5402  
[ir@seaspine.com](mailto:ir@seaspine.com)